|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: PREZISTA
Summary for Tradename: PREZISTA
|
|
Latest news for PREZISTAGilead Sciences' CEO Discusses Q1 2013 Results - Earnings Call Transcript2 May 2013, 7:33 pm First Manhattan Files Preliminary Proxy Materials with SEC for the Election of Six Directors to Vivus’ Board at the ...1 May 2013, 3:05 pm First Manhattan Comments on Addition to Vivus’ Board of Directors1 May 2013, 8:34 am Gilead Fails FDA Approval for 2 HIV Drugs in 4-in-1 Pill29 April 2013, 9:18 am UIC to Bolster Startups with $10M Seed Fund26 April 2013, 1:48 pm UIC launches $10M seed fund to advance startups26 April 2013, 11:51 am Courtesy of Yahoo News | ||||||||||||
Clinical Trials for: PREZISTAA Study to Assess the Pharmacokinetics (Blood Levels) of TMC114 (Darunavir) Taken With Ritonavir and/or TMC125 (Etravirine) and TMC278 (Rilpivirine) in HIV-1 Infected Pregnant Women Status: Recruiting Condition: HIV; HIV Infections; Pregnancy An Observational Study to Evaluate Tolerability of PREZISTA or INTELENCE in HIV-1 Infected Patients Status: Completed Condition: Human Immunodeficiency Virus (HIV) TMC114-C202: A Study of Safety, Efficacy, and Tolerability of TMC114 and Low Dose Ritonavir in HIV-1 Infected Patients Status: Completed Condition: HIV Infections Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects Status: Completed Condition: HIV Infections Safety and Efficacy of Darunavir/Cobicistat/Emtricitabine/GS-7340 Single Tablet Regimen Versus Cobicistat-boosted Darunavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate Fixed Dose Combination in HIV-1 Infected, Antiretroviral Treatment Naive Adults Status: Active, not recruiting Condition: Acquired Immunodeficiency Syndrome; HIV Infections TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir (Rtv) for Adults Coming From Any of the Three Ongoing Tibotec-Sponsored Studies With DRV Status: Active, not recruiting Condition: HIV-1 Infections Darunavir/Ritonavir and Rosuvastatin Pharmacokinetic Study Status: Active, not recruiting Condition: HIV Infections DRIVESHAFT: Darunavir/Ritonavir In HIV-infected Virologically-suppressed Experienced Subjects Status: Recruiting Condition: HIV Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz Status: Active, not recruiting Condition: Hyperlipidemia; HIV Study in Healthy Males to Measure Darunavir and Etravirine in Blood, Seminal Fluid, and Rectal Tissue Status: Completed Condition: HIV/AIDS; HIV Infections Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Janssen Prods | PREZISTA | darunavir ethanolate | SUSPENSION; ORAL | 202895 | Dec 16, 2011 | RX | Yes | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Janssen Prods | PREZISTA | darunavir ethanolate | SUSPENSION; ORAL | 202895 | Dec 16, 2011 | RX | Yes | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Janssen Prods | PREZISTA | darunavir ethanolate | SUSPENSION; ORAL | 202895 | Dec 16, 2011 | RX | Yes | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Janssen Prods | PREZISTA | darunavir ethanolate | SUSPENSION; ORAL | 202895 | Dec 16, 2011 | RX | Yes | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: PREZISTA
| Drugname | Dosage | Strength | RLD | Submissiondate |
| darunavir ethanolate | Tablets | 75 mg, 150 mg, 300 mg, 400 mg and 600 mg | Prezistas | 6/23/2010 |
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc